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Abstract
The ‘‘One world, one health’’ initiative emphasizes the need for new strategies to control human and animal tuberculosis
(TB) based on their shared interface. A good example would be the development of novel universal vaccines against
Mycobacterium tuberculosis complex (MTBC) infection. This study uses the goat model, a natural TB host, to assess the
protective effectiveness of a new vaccine candidate in combination with Bacillus Calmette-Guerin (BCG) vaccine. Thirty-
three goat kids were divided in three groups: Group 1) vaccinated with BCG (week 0), Group 2) vaccinated with BCG and
boosted 8 weeks later with a recombinant adenovirus expressing the MTBC antigens Ag85A, TB10.4, TB9.8 and Acr2
(AdTBF), and Group 3) unvaccinated controls. Later on, an endobronchial challenge with a low dose of M. caprae was
performed (week 15). After necropsy (week 28), the pulmonary gross pathology was quantified using high resolution
Computed Tomography. Small granulomatous pulmonary lesions (, 0.5 cm diameter) were also evaluated through a
comprehensive qualitative histopathological analysis. M. caprae CFU were counted from pulmonary lymph nodes. The
AdTBF improved the effects of BCG reducing gross lesion volume and bacterial load, as well as increasing weight gain. The
number of Ag85A-specific gamma interferon-producing memory T-cells was identified as a predictor of vaccine efficacy.
Specific cellular and humoral responses were measured throughout the 13-week post-challenge period, and correlated with
the severity of lesions. Unvaccinated goats exhibited the typical pathological features of active TB in humans and
domestic ruminants, while vaccinated goats showed only very small lesions. The data presented in this study indicate that
multi-antigenic adenoviral vectored vaccines boosts protection conferred by vaccination with BCG.
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Introduction
Tuberculosis (TB), mainly caused by Mycobacterium tuberculosis, is
one of the most important causes of infectious disease mortality
and morbidity in humans worldwide [1]. Moreover, one-third of
the world’s population is estimated to have latent TB infection
(LTBI), making it one of the most prevalent human infections [2].
M. bovis and M. caprae, also members of the M. tuberculosis complex
(MTBC), are the main causative agents of bovine and caprine TB,
respectively. The latter is considered an emerging disease in a
number of European countries, causing increasing economic losses
to the livestock sector [3–5].
Goats infected with M. caprae may be a source of infection for
cattle, acting as domestic reservoirs of bovine TB [6]. M. caprae has
also been isolated from a wide range of wildlife species [4,7,8], and
even from TB cases in humans [9–11]. However, in the European
Union, there are currently no caprine TB control campaigns. In
endemic areas, vaccination is seen as the best long-term prospect
for TB control in livestock [12]. Reducing the disease prevalence
prior to starting a test and sacrifice-based eradication program
would reduce economic costs for the producers and the public
sector.
Bacillus Calmette-Guerin (BCG), the only currently available
vaccine, displays variable efficacy against human and animal TB
[13–15]. In recent years new subunit vaccines have been
developed to be used as boosters after a previous immunization
with BCG or other live vaccines [16]. Viral delivery of such
subunit vaccines has been widely used [17,18]. Particularly, the
use of adenoviruses as vectors for TB vaccines takes advantage on
their natural tropism for the respiratory epithelium, as well as the
strong immunity they induce [19,20]. Boosting BCG with a
recombinant replication-deficient adenovirus expressing the
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antigen Ag85A showed enhanced protection against TB in small
laboratory animals [20,21], cattle [22,23], and goats [24].
Besides Ag85A, additional potential immunoprotective antigens
are candidates to be included in multi-antigenic formulations.
Among them, the MTBC antigens TB10.4 (Rv0288), TB9.8
(Rv0287) and Acr2 (Rv0251c) have recently been selected for this
purpose on the basis of the induction of an early-CMI in calves
after M. bovis infection of protected animals [25], and have been
included in a new recombinant adenoviral vaccine named AdTBF.
The effect of different doses and administration routes on the
immune responses induced in cattle by BCG priming and AdTBF
boosting have been recently assessed (G.S. Dean et al., unpublished
data).
The aim of this study was to assess the effectiveness of a novel
recombinant adenoviral booster vaccine expressing four MTBC
antigens (Ag85A, TB10.4, TB9.8 and Acr2) to improve BCG
protection against TB in goats challenged with M. caprae, their
natural TB causing agent [26]. In addition to immunological
evaluations and determination of bacterial load, exhaustive post-
mortem analysis based on Computed Tomography (CT) and a
comprehensive histopathological evaluation were used to assess
vaccine efficacy.
Materials and Methods
1. Study design
1. Animals and experimental schedule. Thirty-three female
goat kids (3 month old Murciano-Granadina) obtained from an
official TB-free herd of Murcia Region (South West of Spain)
were selected on the basis of negative results to single
intradermal comparative cervical tuberculin (SICCT) test and
the Bovigam IFN-c assay (Prionics, Schlieren, Switzerland).
Subsequently, animals were randomly divided into three
treatment groups of eleven goats each: Group 1, vaccinated
with BCG; Group 2, vaccinated with BCG and boosted 8
weeks later with a recombinant adenovirus expressing a fusion
protein containing four MTBC antigens (BCG-AdTBF); and
Group 3, unvaccinated controls. Animals were observed daily
for clinical signs and weighted every two weeks during the
experiment.
2. Ethics statement. All animal experimental procedures were
undertaken in accordance with the European Union Laws for
protection of animals used in experimentation (86/609).
Approval was obtained from the Animal Welfare Committee
of the Universitat Auto`noma de Barcelona and the Generalitat de
Catalunya (Permit Number: 6332).
3. Vaccines. For the BCG inoculum preparation, M. bovis BCG
Danish 1331 strain (ATCC, Ref. 35733TM) was sub-cultured in
Middlebrook 7H9 media (BD Diagnostics, Sparks MD, USA)
supplemented with 0.5% (v/v) Tween 80, 40 mM sodium
pyruvate (Sigma-Aldrich, Steinheim, Germany) and 10% (v/v)
albumin dextrose catalase enrichment (BD Diagnostics). It was
incubated for 28 days at 37uC. An aliquot of growth culture
was titrated by platting 10-fold dilutions in phosphate buffered
saline containing 0.05% Tween 80 (PBS-T80) on 7H11 media
(BD Diagnostics) for 28 days at 37uC. The remaining aliquots
were stored at –80uC prior to use. After bacterial count, growth
culture was diluted to 106 CFU/ml by suspension in phosphate
buffered saline (PBS). A dose of 0.5 ml of this suspension was
inoculated subcutaneously in animals of groups 1 and 2 at week
0 of the experiment.
The adenovirus type 5 construct AdTBF, which encodes
Ag85A, TB10.4, TB9.8 and Acr2, was used at 16109 infectious
units (iu) per animal and were injected intramuscularly in animals
of group 2 eight weeks after vaccination with BCG.
1. M. caprae challenge. A field isolate of M. caprae SB0416
(www.Mbovis.org) was sub-cultured in Middlebrook 7H9
supplemented media at 37uC. After 28 days, an aliquot was
platted on 7H11 media and cultured again for 28 days at 37uC
and bacteria were counted as indicated above.
One week prior to challenge, goats were housed in Bio-Safety
Level 3 boxes for acclimatization. Fifteen weeks after BCG
vaccination, all animals were anesthetized with 4–6 mg/kg of
propophol (Propofol LipuroH) and 0.2 mg/kg of midazolam
(DormicumH) administrated intravenously. Subsequently the
animals were challenged through the endobronchial route with a
suspension of approximately 1.56103 CFU of M. caprae as
previously described [27].
2. Post-mortem studies
All goats were euthanized by administration of an intravenous
sodium pentobarbital overdose at week 13 after M. caprae
challenge, i.e. week 28 of the experiment. At necropsy, pulmonary
lymph nodes (LN) were aseptically removed making sure the
pleural lung surface was not sectioned, and the volume of gross
lesions and bacterial load were measured. The number, extension,
and distribution of TB lesions in the lungs were recorded visually
and quantified by Computed Tomography (CT). Microscopic
features of small lung granulomatous lesions were assessed by
histopathological examination.
2.1. Lungs. Lungs were fixed in toto by perfusion with 10%-
buffered formalin through the trachea while being held vertically.
After complete lung distension by the fixative, the trachea was tied,
and whole lungs were immersed into formalin filled containers. Six
month later, fixed lungs were scanned with a high resolution 64-
slice Multi-Detector CT scan (Brillance CT 64-channel, Philips
Medical Systems, Cleveland, Ohio, USA), and sequential slices
Figure 1. Scheme of a granuloma surrounded by satellite
granulomas (SatG). Example of TB small lesion in lung consisting of a
central granuloma (C) surrounded by 8 smaller SatG (S128) character-
ized by variably sized clusters of inflammatory cells contiguous to the
central granuloma, sometimes with presence of MNGC and central
necrosis (e.g. S5). The number of SatG, upon histopathological
assessment of small granulomas, was used as a parameter to evaluate
the tendency of lesions to disseminate.
doi:10.1371/journal.pone.0081317.g001
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were analyzed on a work station (Aquarius Station, TaraRecon,
Foster City, California, USA) as previously described [27]. This
procedure, allowed the calculation of the total volume of
granulomatous lesions relative to the whole lung volume.
Once scanned by CT, lungs were sliced in approximately 1 cm
thick sections to visually examine the lesions. Animals were
classified in three groups depending on the maximum diameter of
the granulomas found in their lungs. Three granuloma diameter
size intervals were defined: , 0.5 cm, Small Granulomas (SG);
0.5–2 cm, Medium Granulomas (MG); and 2 cm, Large Granu-
lomas (LG). The number of affected lung lobes was also recorded.
Representative LG and MG from each goat (when present)
were investigated histopathologically. In addition, five SG from
each animal (with the exception of a goat of the BCG-AdTBF
group which presented only 4 SG) were also selected for
histopathological study to determine possible qualitative morpho-
logical differences between groups. Granulomas were sectioned
through their maximum diameter and embedded in paraffin.
Then, 4 mm sections were stained with hematoxylin and eosin
(HE). Slides were microscopically examined in parallel by two
pathologists (blinded regarding the experimental groups). The
following parameters were scored: 1) Stage of granuloma
development according to the four stages previously defined by
Wangoo et al.: Stage I (Initial), Stage II (Solid), Stage III (Minimal
necrosis) and Stage IV (Necrosis and mineralization) [28]; 2)
number of satellite granulomas (SatG) surrounding the central
lesion (a descriptive scheme is shown in Figure 1); 3) presence of
multinucleated giant cells (MNGC) as previously described [29]: 0,
1 to 10 and . 10 MNGC; 4) central necrosis extension (absence of
necrosis, necrosis comprising , 50%, and $ 50% of granuloma
surface); and 5) mineralization degree: absence, low and high.
2.2. Pulmonary LN. Gross lesions in pulmonary LN (caudal
and cranial mediastinal, right and left tracheobronchial) were
measured as previously described [27]. The volume of visible
lesions of each animal was calculated as 4/36p6r3 (where r is the
lesion radius) taking into account the sphere-like morphology of
the lesions found. Recording of all granuloma diameters was
performed by the same pathologist in order to ensure the same
criterion was followed for all samples.
After gross pathological evaluation, whole pulmonary LN were
homogenized and decontaminated as previously described [27].
The total viable bacterial count in LN was determined by plating
0.1 ml of serial dilutions of LN homogenates on 7H11 agar plates
(BD Diagnostics). The inoculated media were incubated at 37uC
for 28 days. After that, the total CFU count of each LN was
calculated.
3. Assessment of immune responses
1. Antigens and peptides. Bovine tuberculin (PPD-B) and
avian tuberculin (PPD-A) were obtained from CZ Veterinaria
(Porrin˜o, Spain). Recombinant mycobacterial proteins TB9.8,
TB10.4, Ag85A, Acr2 and MPB83 were obtained from Lionex
Figure 2. Body weight after M. caprae infection. Goats were
challenged with 1500 CFU M. caprae at week 15 and weighted weekly
untill the end of the experiment (week 28). Each line represents the
cumulative weight increases (in kg 6 95% CI) in the three treatment
groups from the challenge to the end point.
doi:10.1371/journal.pone.0081317.g002
Figure 3. Quantification of pulmonary pathology and bacterial burden. (A and B) The sum of gross lesions (GL) volumes in lungs (measured
by CT) and thoracic LN (measured by direct visual examination) is expressed in cm3, and the total bacterial counts in thoracic LN are expressed as
Log10-transformed CFU. Horizontal lines indicate mean values. ***P,0.001, one-way ANOVA/Student-Newman-Keuls multiple comparison test. (C)
Correlation between the volume of GL and bacterial counts. Results are divided according to treatment groups (BCG, circles; BCG-AdTBF, diamonds;
and Control, triangles). *P,0.05, Pearson’s correlation (r).
doi:10.1371/journal.pone.0081317.g003
Multi-Antigenic Adenoviral TB Vaccine in Goats
PLOS ONE | www.plosone.org 3 November 2013 | Volume 8 | Issue 11 | e81317
(Braunschweig, Germany). Peptide cocktails ESAT-6/CFP-10
(E/C) and Rv3615c [27], were supplied by AHVLA.
2. IFN-c Whole blood assay. Blood samples were collected
from the jugular vein in heparinized blood tubes. One ml of
whole blood was stimulated in 96-deepwell cell culture plates
(Eppendorf Ibe´rica, Madrid, Spain) with PBS, PPD-B at
10 mg/ml, Ag85A, E/C and Rv3615c at 5 mg/ml, or
phytohemagglutinin (Sigma-Aldrich) at 10 mg/ml. Plasma
supernatants were collected after 24h of culture at 37uC and
5% CO2 and stored at –20uC until tested by Bovigam IFN-c
enzyme-linked immunosorbent assay (ELISA), which was
performed according to the manufacturer’s instructions.
ELISA results were obtained as Optical Density determined
at 450 nm (OD450). Specific reaction was expressed as DOD450
(OD450 of antigen-stimulated sample minus OD450 of non-
stimulated control). The assay was performed every two weeks
throughout the experiment using PPD-B and Ag85A as stimuli.
Peptide cocktail E/C and Rv3615c were also included at weeks
15, 20, 26 and 28.
3. IFN-c Cultured ELISPOT assay. At week 15 (prior to
challenge), Peripheral Blood Mononuclear Cells (PBMC) were
isolated from blood of a subset of 10 randomly selected
vaccinated goats (5 of BCG group and 5 of BCG-AdTBF
group). Blood samples were diluted 1:1 in PBS, separation of
blood cell populations was performed with a gradient
centrifugation using Histopaque-1077 (Sigma-Aldrich). PBMC
were stimulated in 24-well plates (26106 cells/well) with
10 mg/ml of PPD-B in cell culture medium: RPMI 1640
medium (Sigma-Aldrich) supplemented with 10% fetal calf
serum (Sigma-Aldrich), non-essential amino-acids (Sigma-
Aldrich), 561025 M 2-mercaptoethanol, 100 U/ml penicillin
and 100 mg/ml streptomycin sulphate. Cells were incubated at
37uC 5% CO2. Cultured ELISPOT assay was based on a
previously described method [23], briefly, recombinant human
IL-2 (Sigma-Aldrich) was added to cell cultures at a final
concentration of 10 U/ml at days 5 and 8. Half of supernatant
was replaced with fresh cell culture medium without IL-2 at
days 10 and 12. On day 13, 56104 cultured cells/well were
added into ELISPOT plates (MultiScreen HTS, Merck
Millipore, Darmstadt, Germany) previously coated overnight
at 4uC with bovine monoclonal IFN-c antibody (Acris
Antibodies GmbH, Herford, Germany), which recognizes goat
IFN-c, and then blocked with 10% fetal calf serum in RPMI
medium. Cells were stimulated with 5 mg/ml of Ag85A,
TB10.4 and TB9.8 in separated wells, and incubated 24h at
37uC 5% CO2. Cultures were performed in the presence of
autologous antigen presenting cells (obtained from PBMC
isolated at week 15, as described in [30]). After that, biotin-
labelled bovine monoclonal IFN-c antibody (Acris Antibodies
GmbH), which also recognizes goat IFN-c, and phosphatase-
conjugated streptavidin (Life Technologies S.A., Madrid,
Spain) were added to develope the spots. Spot-Forming Cells
(SFC) were revealed and counted as previously described [23],
and the number of SFC/ml was calculated.
4. Serological tests. Humoral responses to vaccination and M.
caprae infection were studied by carrying out IgG indirect
ELISAs to the MTBC protein MPB83 and the four antigens
expressed by the adenoviral vaccine (Ag85A, Acr2, TB9.8 and
TB10.4). Ninety-six-well plates were coated for each of the five
antigens separately (Nunc Maxisorp; Thermo Fisher Scientific,
Roskilde, Denmark) at a final concentration of 0.5 mg/ml each,
diluted in carbonate/bicarbonate buffer. The plates were
incubated overnight at 4uC. For the MPB83-specific ELISA,
plasma samples from all goats were analysed at weeks 0, 4, 8,
15 and then every two weeks, whereas for the four AdTBF-
antigens ELISAs plasma samples were analyzed at weeks 0, 8,
9, 10 and then every two weeks. The IgG ELISAs were
performed as described previously [24]. PPD-B and PPD-A
intradermal inoculations were performed at week 26 following
the standard procedures for SICCT test in order to generate a
boost-effect on humoral responses at week 28.
Figure 4. Extension of gross lesions and distribution in the
lungs. Individual relationship between the number of lung lobes with
TB lesions (out of 7) and the classification according to the maximum
sized granuloma found in the lungs (SG, Small Granuloma: , 0.5 cm
diameter, clear grey; MG, Medium Granuloma: 0.5–2 cm diameter, grey;
and LG, Large Granuloma: . 2 cm diameter, black). Results are divided
according to the three groups: BCG-AdTBF (A), BCG (B) and Control (C).
doi:10.1371/journal.pone.0081317.g004
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4. Statistical analyses
One-way ANOVA with Student-Newman-Keuls multiple
comparison test was used for comparisons among groups in terms
of differences in weight increase, volume of lesions, number of
affected lobes, number of SatG and bacterial load (log10-
transformed data). Whole blood IFN-c responses and serological
tests were compared by non-parametric Kruskal-Wallis test with
post hoc Mann-Whitney or Wilcoxon test, whereas IFN-c SFC
differences between vaccinated groups were compared by
Student’s unpaired two-sample T-test. Differences in observed
frequencies of qualitative histopathological features among groups
were assessed by chi-squared test. Correlations between post-
mortem parameters, as well as between IFN-c cultured ELISPOT
results and post-mortem parameters were assessed by using
Pearson’s correlation, whereas the rest of immunological responses
were compared with post-mortem parameters by employing non-
parametric Spearman rank test. Data analysis was performed
using SPSS statistical package version 19.0 (IBM Inc. Chicago, IL,
USA).
Results
1. Clinical signs and body weight
Clinical signs typical of caprine TB were monitored from the M.
caprae challenge to the end point of the study. Coughing was
observed in 7/11 BCG, 2/11 BCG-AdTBF and 6/11 unvacci-
nated control goats. The mean body weight increase during this
period was significantly lower in unvaccinated control animals
(249 g/week, 95% CI: 230-269) in comparison to BCG-AdTBF
group (403 g/week, 95% CI: 383-423, P,0.001) and BCG group
(351 g/week, 95% CI: 331-370, P,0.05). The weight increase
during the post-challenge period of the different groups is shown in
Figure 2.
2. Gross pathology and bacteriology
All animals presented macroscopic TB lesions at necropsy
exhibiting a wide range of sizes between groups. Large lesions
often developed conspicuous liquefaction and cavities. TB lesions
were mainly restricted to the respiratory system, with the
exception of 4 unvaccinated goats which also showed extra-
pulmonary TB lesions in liver (n = 3), pericardium (n = 2) and
spleen (n = 1).
The sum of gross lung and LN lesion volume and the bacterial
load in respiratory LN, are shown in Figure 3 (A-B). Vaccinated
groups showed a significant reduction of gross lesions (mean
volume of gross lesions) and bacterial load (mean Log10 CFU/LN)
in comparison to the unvaccinated group (P,0.001). Significant
differences were also found in the volume of gross lesions between
the two vaccinated groups. The BCG-AdTBF group showed lower
volume of gross lesions in lungs (mean Log10 cm
3: 0.9, 95% CI:
0.7-1.2; P,0.05) and LN (mean Log10 mm
3: 2.3, 95% CI: 2.1-2.5;
P,0.05) compared with BCG group (mean Log10 cm
3: 1.3, 95%
CI: 1.1-1.4; and mean Log10 mm
3: 2.9, 95% CI: 2.6-3.2;
respectively). A direct correlation between bacterial load and total
volume of gross lesions was only found in unvaccinated animals (r
= 0.684, P,0.05, Figure 3C). In vaccinated animals, however, the
gross lesion volume reduction was more pronounced than was the
bacterial load reduction.
The extension of gross lesions in the lung was also assessed to
classify animals depending on the size of the biggest granuloma
found in their lungs (maximum granuloma size). Ten out of 11
Table 1. Histopathological analysis of pulmonary small granulomas (, 0.5 cm diameter).
No. of granulomas per group (%)
Granuloma feature Value BCGa BCG-AdTBFb Controla
Necrosis
Low or none 10 (18) 9 (17) 20 (36)
High 45 (82)* 45 (83)* 35 (64)
Mineralization
Low or none 34 (62) 34 (63) 44 (80)
High 21 (38) 20 (37) 11 (20)
Developmental stage
I 1 (2) 0 (0) 1 (2)
II 6 (11) 6 (11) 12 (22)
III 25 (45) 38 (70)* 26 (47)
IV 23 (42)* 10 (19) 16 (29)
No. of MNGCc
, 10 or none 23 (42) 10 (19) 16 (29)
$ 10 32 (58) 44 (81)* 39 (71)
No. of satellite granulomas
None 15 (27) 9 (17) 7 (13)
1–3 28 (51) 28 (52) 20 (36)
$ 4 12 (22) 17 (31) 28 (51)**
aFive granulomas /animal (N = 55).
bOne animal only presented 4 granulomas (N = 54).
cMNGC: multinucleated giant cells.
*P,0.05, ** P,0.01 (Chi-squared test).
doi:10.1371/journal.pone.0081317.t001
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unvaccinated goats developed one or more LG, whereas these
granulomas were found only in 1 BCG and 1 BCG-AdTBF
vaccinated goats. Eleven animals showed at least one MG and no
LG (6 BCG, 4 BCG-AdTBF and 1 control) and, finally, ten
vaccinated goats (4 BCG and 6 BCG-AdTBF) showed only SG.
These differences in maximum granuloma size between vaccinat-
ed and unvaccinated groups were statistically significant
(P,0.001).
Vaccinated goats also presented lower lesion dissemination
amongst lung lobes. The mean number of affected lung lobes was
Figure 5. Staging of small granulomas (SG) by histopathological analysis. Representative developmental stages of the SG found in
formalin-fixed lungs. (A-B) Stage IV. SG from 2 BCG-vaccinated goats. Encapsulation is complete. Extensive central necrosis with high degree of
mineralization. (C-D) Stage III. SG from 2 BCG-AdTBF-vaccinated goats. Incomplete encapsulation. Macrophages and lymphocytes surrounding the
central necrosis and mineralization. Note the formation in C of 2 satellite granulomas (SatG, S1 and S2). S2 is surrounded by a thin mantle of fibroblasts
(arrowheads) which is connected to the intralobular septa (arrow). (E) Stage II. SG from an unvaccinated goat, presenting an irregular outline, central
necrosis without mineralization and SatG formation. (F) Stage I. SG from an unvaccinated goat. Unstructured lesion presenting a diffuse mixture of
inflammatory cells, without a distinguishable necrotic core.
doi:10.1371/journal.pone.0081317.g005
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of 2.7 (95% CI: 2.3-3.2) in the BCG group and of 2.5 (95% CI:
1.9-3.2) in the BCG-AdTBF group, both of them significantly
lower than that found in the control group (4.7, 95% CI: 3.8-5.7,
P,0.001). The distribution of goats in each group with regard to
maximum granuloma size classification and the dissemination of
gross lung lesions (number of affected lobes) are shown in Figure 4.
3. Histopathological analysis
There were no evident structural differences among groups with
regard to LG and MG. Typical advanced granulomas were seen,
showing prominent and multifocal caseous necrosis, extensive
areas of mineralization, and irregular margins with epithelioid cells
and some MNGC surrounding the necrosis. In contrast, qualita-
tive structural differences were found in SG among groups (Table
1). A total of 164 SG were analyzed (55 from BCG group, 54 from
BCG-AdTBF group and 55 from Control group). Vaccinated
goats had a higher proportion of SG with higher grade of necrosis
(83%, P,0.05), as well as more mineralization (38%, albeit not
statistically significant) in comparison to unvaccinated controls
(64% and 20% respectively). BCG and BCG-AdTBF groups
showed a significantly higher frequency of SG in advanced
developmental stages (IV and III respectively, P,0.05). Examples
of representative SG of vaccinated groups are shown in Figure 5
(A-D). By contrast, unvaccinated animals presented a higher
proportion of SG at early stages (24% at stages I and II), showing
poorly delimitated microscopic lesions with a higher number of
SatG (51% with $ 4 SatG, P,0.01, Figure 5E-F). The mean
number of SatG in each animal correlated positively with both the
volume of gross lesions and the number of affected lung lobes (r =
0.418, P,0.05; r = 0.546, P,0.01; respectively).
Vaccinated animals showed a higher proportion of SG at later
stages with partial or complete encapsulation (i.e. stages III and
IV, Figure 5A-D). These lesions showed highly organized structure
containing a very low proportion of lymphocytes and macrophag-
es surrounding the central necrotic area. On the other hand,
microscopic lesions observed in many unvaccinated animals
showed SG at early-stages, with a poorly organized mixed
inflammatory infiltrate composed of lymphocytes, macrophages
and neutrophils and lower necrosis extension (see Figure 5E-F).
Unvaccinated goats frequently showed SG which opened to the
bronchiolar lumen, emptying its content into the airways leading
to the formation of small cavities (Figure 6).
4. Immune responses following vaccination and
challenge
The whole blood IFN-c responses to E/C and Rv3615c-specific
showed significant differences among groups at week 20, moment
at which the peak response was reached in unvaccinated animals
(Figure 7). At this time point, the mean E/C-specific IFN-c
response in the control group was significantly higher than in the
BCG (P,0.01) and BCG-AdTBF (P,0.05) groups. Also, the mean
Rv3615c-specific IFN-c response in the control group was
significantly higher than in both vaccinated groups (P,0.05). At
the rest of time points, responses were not significantly different
among groups.
IFN-c responses to PPD-B and Ag85A were followed-up
throughout all the experiment. Moderate PPD-B-specific IFN-c
responses were detected from 2 weeks after BCG vaccination up to
the challenge point (week 15) in the two vaccinated groups (data
not shown). A dramatic increase of IFN-c responses to PPD-B was
observed in the three experimental groups after M. caprae
challenge. These responses were maintained up to the end of
the experiment without significant differences among groups
(Figure 7). Ag85A-specific IFN-c responses were undetectable
throughout the experiment until two weeks after AdTBF
inoculation (week 10), when they were significantly higher in the
BCG-AdTBF group (mean DOD: 0.085, 95% CI: 0.021-0.149)
compared with BCG (mean DOD: 0.025, 95% CI: 0-0.05,
P,0.05) and control (mean DOD: 0.007, 95% CI: 0.04-0.01,
P,0.01) groups.
Ex vivo IFN-c responses to E/C and Rv365c were assessed as
correlates of disease progression. At week 20 of the experiment
(when significant differences among groups were found), IFN-c
responses to both E/C and Rv3615c correlated positively both
with the total volume of gross lesions (Spearman’s r: 0.388,
P,0.05; 0.519, P,0.01; respectively) and with the bacterial load
(Spearman’s r: 0.559, P,0.001; 0.4, P,0.05; respectively).
Results of the IFN-c cultured ELISPOT performed prior to
challenge (week 15) were also compared with post-mortem
parameters. Figure 8 shows the correlations between IFN-c
antigen-specific SFC and the total volume of gross lesions in 10
vaccinated goats (5 from BCG group and 5 from BCG-AdTBF
group). Only Ag85A-specific SFC showed significant inverse
correlation with gross lesions (r = –0.557, P,0.05). Even though
without statistical significance, slightly inverse correlation of SFC
specific to TB9.8 with the volume of gross lesions was also
obtained (r = –0.276). No evident correlation was found between
cultured ELISPOT results and bacterial counts (data not shown).
Mean IgG responses to AdTBF-encoded antigens in BCG-
AdTBF prime-boosted goats are shown in Figure 9. Two peaks
were observed, one at two weeks after AdTBF-immunization and
the second two weeks after PPD-B and PPD-A intradermal
inoculations (weeks 10 and 28 respectively, Figure 9A). At these
time points significant differences were found among the different
antigen-specific antibody responses (Figure 9B). Humoral respons-
es to AdTBF-encoded antigens were undetectable in the other two
groups throughout the experiment.
The antibody responses to M. caprae were measured as MPB83-
specific IgG. At week 20, a peak of IgG levels was found in the
control group (mean DOD 1.2, 95% CI: 0.2-2.1), whereas IgG
levels in vaccinated animals were practically undetectable in the
two vaccinated groups (both with mean DOD: 0.01, 95% CI: 0-
0.03) and, thus, were significantly lower compared with the control
group (P,0.001). At this time point, the IgG responses to MPB83
correlated positively with the total volume of gross lesions
(Spearman’s r: 0.524, P,0.01) and with the bacterial load
(Spearman’s r: 0.481, P,0.01). All animals presented higher IgG
levels at week 28 (after the intradermal tuberculin boost effect) and
statistically significant differences were not found among the three
groups (Control group mean DOD: 2.9, 95% CI: 2.1-3.7; BCG
group mean DOD: 2.4, 95% CI: 1.6-3.2; BCG-AdTBF group
mean DOD: 2, 95% CI: 1.1-2.8).
Figure 6. Progression of caseous necrosis to cavitary lesions. (A) The caseous necrosis in the centre of the granuloma progresses to
liquefaction and, if not effectively encapsulated, the necrotic reaction destroys the epithelium of an adjacent bronchiole, emptying the content of the
liquefied lesion into the airways. (B). Large cavitation of pulmonary parenchyma, originates from progressive liquefaction of confluent granulomatous
lesions, observed macroscopically in all unvaccinated goats.
doi:10.1371/journal.pone.0081317.g006
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Discussion
Recently, our research group, in collaboration with other
partners involved in human and animal TB vaccine development,
proposed domestic goats as a new experimental TB model to be
used in trials with the advantage of its simple husbandry and
relatively low economical costs [27]. This model has been used
herein to assess the efficacy of AdTBF, a new TB vaccine booster
candidate containing four MTBC antigens, in combination with
BCG (heterologous prime-boost procedure: BCG priming and
AdTBF boosting). BCG-AdTBF induced improved protection
compared to the protection observed in animals vaccinated only
with BCG. Namely a reduction of the bacterial load and the
severity of the pathology were observed.
A previous study using BCG and an Ag85A-monovalent-
booster vaccine with the same vaccination strategy yielded similar
results in terms of protection [24]. In both experiments, BCG-
primed and adenoviral-boosted animals showed a mean volume of
lung lesions of around 11 cm3 (less than 1% of lung involvement),
and a bacterial load in pulmonary LN of approximately 3 Log10 (a
reduction of 1 Log10 compared to unvaccinated animals). In
contrast, despite experimental goats were of the same age in the
two studies, BCG-AdTBF group showed a statistically significant
increase in the weight gain compared to BCG and control groups,
while there were no differences in weight gain among groups in the
first study. Regrettably, due to logistical constraints BCG-AdTBF
vaccination could not be directly compared in the present study
with BCG-AdAg85A.
Unvaccinated goats, after challenge with M. caprae, progressed
to clinical disease, while vaccinated goats (particularly BCG-
AdTBF treated animals), showed mainly small, well-delimitated
lesions, with microscopic features similar to granulomas found in
human LTBI [31]. Goat and human lungs share essential
morphologic characteristics, particularly in their intralobular
septation by connective tissue (see Figure 5C). These structures
may facilitate granuloma encapsulation and containment of
mycobacterial spreading [32]. In contrast, small laboratory animal
models often used in TB vaccine trials, such as mice, guinea pigs,
rabbits and even macaques, do not show this lung compartmen-
talization [33].
Furthermore, goats have the advantage of reproducing the
typical features of human active TB, such as lung cavitary lesions,
which are frequently found in naturally infected goats [34] and are
also induced upon experimental infection [27]. Even though cattle
infected with M. bovis show similar lung granulomatous reaction
and immune response to TB as humans do [35], evident cavitary
lesions are difficult to induce experimentally [36].
To establish a relationship between the protective effect of
vaccination and the lesion pattern, morphological features of small
granulomas (SG, lesions with , 0.5 cm diameter) were investi-
gated. Our aim was to determine if qualitative differences existed
in a comparable lesion which could be found in the three groups of
animals. The four stage classification of LN granulomas developed
by Wangoo et al. for experimental M. bovis infection in calves [28]
was followed for this purpose. Unvaccinated goats showed higher
proportion of SG at initial developmental stages, while most SG
from vaccinated animals showed characteristics of older, more
evolved lesions, namely, high degree of necrosis, mineralization
and partial or total encapsulation by connective tissue.
It could be speculated that poorly organized SG (found mainly
in unvaccinated goats), without evident arrangement in layers of
lymphocytes and macrophages, would easily progress to bigger
granulomatous lesions. Indeed, all unvaccinated goats presented a
Figure 7. Antigen-specific IFN-c responses after M. caprae
challenge. Determination by ELISA of the IFN-c released after
peripheral blood stimulation with: (A), bovine PPD (PPD-B); (B), ESAT-
6/CFP-10 peptide cocktail (E/C); and (C), Rv3615c protein. The results are
expressed as mean DOD450 6 95% CI for the 3 treatment groups (BCG,
BCG-AdTBF and Control). *P,0.05, **P,0.01, Kruskal-Wallis/Mann-
Withney post-hoc test.
doi:10.1371/journal.pone.0081317.g007
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variable number of LG, many of them liquefacted (shown at
Figure 4).
At the microscopic level, we have introduced an additional
parameter to evaluate lesion containment: the presence of small
satellite granulomas (SatG) surrounding a central lesion. Histo-
logical examination suggests that SatG surrounding the main
lesion will likely progress to new SG, ultimately evolving to
coalescent larger lesions. The positive correlation between the
extent of the pathology (volume of gross lesions and number of
affected lung lobes) and the mean number of SatG (per animal)
also supports this speculation.
SG in stages III and IV resemble lesions found in human LTBI
[31]. Rapid granuloma encapsulation, preventing its liquefaction,
cavitation and bacillary drainage to the airways, has been
hypothesized as a key step for containing TB infection, and as
an explanation for the induction of a human-like LTBI in a
minipig TB model [32].
Additionally, the absence of big granulomatous lesions in BCG-
AdTBF vaccinated animals is consistent with their lower systemic
Th1 pro-inflammatory response post-challenge. Moreover, in
some vaccinated individuals the gross lesion volume was propor-
tionally more reduced than was the bacterial load found in its
draining LN. This is consistent with the lower specific IFN-c
response against antigens secreted by the growing bacilli (i.e.
ESAT-6, CFP-10 and Rv3615c) in vaccinated animals, suggesting
that the bacterial load found might be mainly composed of an in
Figure 8. Vaccine-induced memory T cells correlated with infection outcome. IFN-c cultured ELISPOT responses to 3 AdTBF antigens
(Ag85A, TB9.8 and TB10.4) performed prior to M. caprae-challenge (week 15) in 10 vaccinated goats (5 BCG [N] and 5 BCG-AdTBF [X]). Figure shows
the correlations of Spot Forming Cells (SFC) with the total volume of gross lesions (GL) measured post-mortem. *P,0.05, Pearson’s correlation.
doi:10.1371/journal.pone.0081317.g008
Figure 9. Vaccine and challenge-induced antibody responses. (A) Kinetics of the IgG specific responses in the 11 goats primed with 56105
CFU BCG (week 0), boosted with 109 PFU AdTBF (week 8) and challenged with 1500 CFU M. caprae (week 15), to the four AdTBF antigens (Acr2,
Ag85A, TB10.4 and TB9.8). SICCT: single intradermal comparative cervical tuberculin test (week 26). The dashed boxes indicate the IgG responses at
weeks 10 and 28. (B) Comparison of IgG responses at 2 weeks after AdTBF immunization (week 10), and 2 weeks after SICCT test (week 28). *P,0.05,
***P,0.001, Kruskal-Wallis/Wilcoxon post-hoc test.
doi:10.1371/journal.pone.0081317.g009
Multi-Antigenic Adenoviral TB Vaccine in Goats
PLOS ONE | www.plosone.org 10 November 2013 | Volume 8 | Issue 11 | e81317
vivo non-replicating bacilli subpopulation. This is in accordance to
what occurs in TB murine model after short-term chemotherapy
[37], used to study the nature of human LTBI. These observations
suggest that vaccine-dependent pathogenesis of granuloma
formation and development might occur in the goat TB model.
The cultured IFN-c ELISPOT is an innovative method for
measuring memory T-cell immunity, which has been successfully
used as predictor of vaccine efficacy against infections caused by
intracellular pathogens such as malaria [38] or TB [23].
Accordingly, we found a negative correlation between Ag85A-
specifc SFC and the total volume of gross lesions (lungs and LN).
These results endorse the measurement of specific IFN-c-
producing memory cells as a predictor of TB vaccine efficacy.
Interestingly, only the cultured ELISPOT responses against
Ag85A correlated significantly with protection (or negatively with
extent of disease), with TB9.8 showing a non-significant trend,
whilst responses to TB10.4 did not associate with disease at all. It is
interesting to speculate that Ag85A, and to a lower degree TB9.8,
are protective antigens, whilst TB10.4 may only have a minimal
contribution to the overall protective immunity. However, this
hypothesis needs to be tested using recombinant adenoviral
vaccines expressing only single antigens. Unfortunately, it was
not possible to measure Acr2 responses in this assay.
Concerning the immune correlates of infection assessed in the
present study, the positive correlation of the specific IFN-c levels to
E/C and Rv3615c, as well as the specific antibody levels to the
surface protein MPB83, with the severity of the pathology, are in
agreement with other studies performed in calf and goats
experimentally challenged with M. bovis and M. caprae respectively
[24,27,39,40].
Recently, the modified Vaccinia Ankara virus expressing
antigen 85A (MVA85A), the first vaccine candidate after BCG,
failed to confer statistically significant enhanced protection against
TB disease or infection in 2794 South African infants, compared
with BCG alone [41]. Despite this result, several other viral-
delivered vaccines in clinical trials have shown improved
protection in a number of animal models [21,23,42,43]. Indeed,
the results presented herein show enhanced protection of BCG-
primed and AdTBF-boosted goats after the M. caprae challenge.
However, our findings are far away from the goal of obtaining a
vaccine that prevents mycobacterial infection. In the last decade,
the mucosal immunity in the respiratory airways has been
receiving major attention in inducing protection against certain
infectious diseases [44]. The availability of mucosal antibodies at
the alveolar space might prevent bacilli reaching the lung from
establishing the initial infection [45]. A future generation of
vaccines could be focused on inducing pre-existing antibodies at
the site of infection to eradicate the mycobacteria before they can
hide within the target cells [46]. In this regard, BCG prime
followed by mucosal administration of AdAg85A have already
showed encouraging results in terms of protection against M.
tuberculosis in small animal models [20,21] and have shown similar
immunogenicity than other routes of administration in cattle
[22,47]. Future trials using the experimental goat TB model could
be directed towards: a) the use of M. tuberculosis challenge instead of
M. caprae and b) the use mucosal administration routes of TB
vaccine.
Following the ‘‘One health’’ approach, promoted by the WHO
and OIE, the present study addresses the public and animal health
challenge of TB control and eradication. Using goats as a large
animal model of TB, we have shown an improvement of
protection, when BCG vaccinated goats are boosted with AdTBF.
These results support further evaluation of adenoviral-based multi-
antigenic TB vaccines in clinical trials.
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